1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
[CROSSREF] [PUBMED]
2. Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008;19:79-86.
[CROSSREF] [PUBMED]
3. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int 2001;12:903-8.
[CROSSREF] [PUBMED]
4. Brenneman SK, Barrett-Connor E, Sajjan S, Markson LE, Siris ES. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809-16.
[CROSSREF] [PUBMED]
5. Brown JP, Adachi JD, Schemitsch E, Tarride JE, Brown V, Bell A, et al. Mortality in older adults following a fragility fracture: real-world retrospective matched-cohort study in Ontario. BMC Musculoskelet Disord 2021;22:105.
[CROSSREF] [PUBMED] [PMC]
6. Tarride JE, Adachi JD, Brown JP, Schemitsch E, Slatkovska L, Burke N. Incremental costs of fragility fractures: a population-based matched-cohort study from Ontario, Canada. Osteoporos Int 2021 Feb 18 [Epub].
https://doi.org/10.1007/s00198-021-05877-8
.
[CROSSREF]
7. Papaioannou A, Giangregorio L, Kvern B, Boulos P, Ioannidis G, Adachi JD. The osteoporosis care gap in Canada. BMC Musculoskelet Disord 2004;5:11.
[CROSSREF] [PUBMED] [PMC]
8. Bell A, Hill MD, Herman RJ, Girard M, Cohen E. Canadian REduction of Atherothrombosis for Continued Health (REACH) Registry Steering Committee. Management of atherothrombotic risk factors in high-risk Canadian outpatients. Can J Cardiol 2009;25:345-51.
[CROSSREF] [PUBMED] [PMC]
9. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res 2012;27:2039-46.
[CROSSREF] [PUBMED]
10. Mitchell PJ. Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep 2013;11:52-60.
[CROSSREF] [PUBMED]
11. Hawley S, Javaid MK, Prieto-Alhambra D, Lippett J, Sheard S, Arden NK, et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing 2016;45:236-42.
[CROSSREF] [PUBMED] [PMC]
12. Metcalfe D, Zogg CK, Judge A, Perry DC, Gabbe B, Willett K, et al. Pay for performance and hip fracture outcomes: an interrupted time series and difference-in-differences analysis in England and Scotland. Bone Joint J 2019;101-B:1015-23.
[PUBMED] [PMC]
13. Gonzalez-Quevedo D, Bautista-Enrique D, Perez-Del-Rio V, Bravo-Bardaji M, Garcia-de-Quevedo D, Tamimi I. Fracture liaison service and mortality in elderly hip fracture patients: a prospective cohort study. Osteoporos Int 2020;31:77-84.
[CROSSREF] [PUBMED]
14. Binkley N, Blank RD, Leslie WD, Lewiecki EM, Eisman JA, Bilezikian JP. Osteoporosis in crisis: it’s time to focus on fracture. J Bone Miner Res 2017;32:1391-4.
[CROSSREF] [PUBMED]
15. Leslie WD, Lix LM. Comparison between various fracture risk assessment tools. Osteoporos Int 2014;25:1-21.
[CROSSREF] [PUBMED]
16. Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis 2015;74:1958-67.
[CROSSREF] [PUBMED]
17. Burden AM, Tanaka Y, Xu L, Ha YC, McCloskey E, Cummings SR, et al. Osteoporosis case ascertainment strategies in European and Asian countries: a comparative review. Osteoporos Int 2021;32:817-29.
[CROSSREF] [PUBMED]
18. McCloskey E, Kanis JA, Johansson H, Harvey N, Oden A, Cooper A, et al. FRAX-based assessment and intervention thresholds: an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 2015;26:2091-9.
[CROSSREF] [PUBMED]
19. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017;12:43.
[CROSSREF] [PUBMED] [PMC]
20. Giangregorio LM, Leslie WD. Manitoba Bone Density Program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. J Bone Miner Res 2010;25:1400-5.
[CROSSREF] [PUBMED]
21. Johansson H, Siggeirsdottir K, Harvey NC, Oden A, Gudnason V, McCloskey E, et al. Imminent risk of fracture after fracture. Osteoporos Int 2017;28:775-80.
[CROSSREF] [PUBMED]
22. Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int 2011;22:2395-411.
[CROSSREF] [PUBMED]
23. Beaudoin C, Jean S, Moore L, Gamache P, Bessette L, Ste-Marie LG, et al. Number, location, and time since prior fracture as predictors of future fracture in the elderly from the general population. J Bone Miner Res 2018;33:1956-66.
[CROSSREF] [PUBMED]
24. Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures. Osteoporos Int 2020;31:1817-28.
[CROSSREF] [PUBMED] [PMC]
25. Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, et al. The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture. Osteoporos Int 2021;32:47-54.
[CROSSREF] [PUBMED]
26. Kanis JA, Johansson H, Harvey NC, Lorentzon M, Liu E, Vandenput L, et al. An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines: A report for the National Osteoporosis Guideline Group (NOGG). Osteoporos Int 2021 Apr 4 [Epub].
https://doi.org/10.1007/s00198-021-05942-2
.
[CROSSREF]
27. Kim HY, Jang EJ, Park B, Kim TY, Shin SA, Ha YC, et al. Development of a Korean Fracture Risk Score (KFRS) for predicting osteoporotic fracture risk: analysis of data from the Korean National Health Insurance Service. PLoS One 2016;11:e0158918.
[CROSSREF] [PUBMED] [PMC]
28. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 2020;105:dgaa048.
[CROSSREF] [PUBMED]
29. Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018;391:230-40.
[CROSSREF] [PUBMED]
30. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017;377:1417-27.
[CROSSREF] [PUBMED]
31. Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 2017;32:198-202.
[CROSSREF] [PUBMED]
32. McClung MR. Role of bone-forming agents in the management of osteoporosis. Aging Clin Exp Res 2021;33:775-91.
[CROSSREF] [PUBMED]
33. Brown JP. Antiresorptives: safety concerns-clinical perspective. Toxicol Pathol 2017;45:859-63.
[CROSSREF] [PUBMED]
34. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 2015;30:3-23.
[CROSSREF] [PUBMED]
35. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
[CROSSREF] [PUBMED]
36. Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014;29:1-23.
[CROSSREF] [PUBMED]
37. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513-23.
[CROSSREF] [PUBMED]
38. Watts NB, Grbic JT, Binkley N, Papapoulos S, Butler PW, Yin X, et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years. J Clin Endocrinol Metab 2019;104:2443-52.
[CROSSREF] [PUBMED]
39. Ng AC, Png MA, Mohan PC, Koh JS, Howe TS. Atypical femoral fractures: transverse morphology at lateral cortex is a critical feature. J Bone Miner Res 2014;29:639-43.
[CROSSREF] [PUBMED]
40. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, et al. Denosumab or zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 2016;101:3163-70.
[CROSSREF] [PUBMED] [PMC]
41. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, et al. Relationship between bone mineral density t-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res 2019;34:1033-40.
[CROSSREF] [PUBMED]
42. Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer DC, Black DM, et al. Goal-directed treatment for osteoporosis: a progress report from the ASBMR-NOF working group on goal-directed treatment for osteoporosis. J Bone Miner Res 2017;32:3-10.
[CROSSREF] [PUBMED]
43. Lewiecki EM. Osteoporosis: treat-to-target. Curr Osteoporos Rep 2017;15:103-9.
[CROSSREF] [PUBMED]
44. Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, et al. Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 2019;34:632-42.
[CROSSREF] [PUBMED]
45. Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int 2019;30:1733-43.
[CROSSREF] [PUBMED]
46. Eastell R, Hannon RA, Wenderoth D, Rodriguez-Moreno J, Sawicki A. Effect of stopping risedronate after long-term treatment on bone turnover. J Clin Endocrinol Metab 2011;96:3367-73.
[CROSSREF] [PUBMED] [PMC]
47. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38.
[CROSSREF] [PUBMED]
48. Brown JP, Morin S, Leslie W, Papaioannou A, Cheung AM, Davison KS, et al. Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician 2014;60:324-33.
[PUBMED] [PMC]
49. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012;27:243-54.
[CROSSREF] [PUBMED]
50. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2015;30:934-44.
[CROSSREF] [PUBMED]
51. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809.
[CROSSREF] [PUBMED]
52. Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016;31:16-35.
[CROSSREF] [PUBMED]
53. Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwinski E, Bone HG, et al. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int 2020;31:181-91.
[CROSSREF] [PUBMED]
54. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2019;104:1595-622.
[CROSSREF] [PUBMED]
55. Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011;96:972-80.
[CROSSREF] [PUBMED]
56. Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317-26.
[CROSSREF] [PUBMED]
57. Solling AS, Harslof T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 2020;35:1858-70.
[CROSSREF] [PUBMED]
58. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018;33:190-8.
[CROSSREF] [PUBMED]
59. Ferrari S, Butler PW, Kendler DL, Miller PD, Roux C, Wang AT, et al. Further nonvertebral fracture reduction beyond 3 years for up to 10 years of denosumab treatment. J Clin Endocrinol Metab 2019;104:3450-61.
[CROSSREF] [PUBMED]